Hennessey M H, Rayburn W F, Stewart J D, Liles E C
Section of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of Oklahoma College of Medicine, Oklahoma City, OK 73190, USA.
Am J Obstet Gynecol. 1998 Nov;179(5):1204-9. doi: 10.1016/s0002-9378(98)70132-2.
Our purpose was to compare the efficacy of commercial prostaglandin E2 products, in combination with oxytocin, for the initiation of labor among pregnancies with pre-eclampsia.
Patients with pregnancy-induced hypertension and with either proteinuria or other end-organ damage were enrolled if they had an unfavorable Bishop score (</=4) and were eligible to undergo labor. Each was randomly assigned to receive prostaglandin E2 either as a 0. 5-mg intracervical gel (Prepidil) or as a 10-mg controlled-release vaginal insert (Cervidil). Oxytocin was begun either immediately after instillation of the gel or was delayed until after removal of the insert.
Of the 70 patients, there were no differences between the Prepidil (n = 34) and the Cervidil (n = 36) groups in maternal demographics, gestational age, parity, and predose Bishop score. There was a mean 14.3-hour difference in the duration from beginning therapy until vaginal delivery in the Prepidil group than in the Cervidil group (11.5 +/- 2.3 hours vs 25.8 +/- 6.9 hours, P <. 001). This time difference, which favored use of Prepidil-immediate oxytocin, remained significant after parity (nulliparous: 20 hours, P <.005; multiparous: 12 hours, P <.01) and gestational age were controlled (preterm: 15.5 hours, P <.01; term: 13.3 hours, P <.01).
Use of combined intracervical prostaglandin E2 gel-immediate oxytocin therapy was more effective in shortening the induction-to-vaginal delivery time than use of a controlled-release prostaglandin E2 vaginal insert.
我们的目的是比较商用前列腺素E2产品与缩宫素联合使用在子痫前期妊娠引产中的疗效。
妊娠高血压且伴有蛋白尿或其他终末器官损害的患者,若其 Bishop 评分不佳(≤4分)且符合引产条件,则纳入研究。将每位患者随机分配,接受0.5毫克宫颈内凝胶(普贝生)或10毫克控释阴道栓剂(欣普贝生)形式的前列腺素E2治疗。缩宫素在凝胶滴注后立即开始使用,或推迟至取出栓剂后使用。
70例患者中,普贝生组(n = 34)和欣普贝生组(n = 36)在产妇人口统计学特征、孕周、产次和给药前Bishop评分方面无差异。普贝生组从开始治疗到阴道分娩的持续时间比欣普贝生组平均短14.3小时(11.5±2.3小时 vs 25.8±6.9小时,P<.001)。在控制产次(初产妇:20小时,P<.005;经产妇:12小时,P<.01)和孕周(早产:15.5小时,P<.01;足月产:13.3小时,P<.01)后,这种有利于使用普贝生 - 立即使用缩宫素的时间差异仍然显著。
与使用控释前列腺素E2阴道栓剂相比,联合使用宫颈内前列腺素E2凝胶 - 立即使用缩宫素疗法在缩短引产至阴道分娩时间方面更有效。